Human iPSC-derived MSCs from aged individuals acquire a rejuvenation signature
The use of primary mesenchymal stem cells (MSCs) is fraught with ageing-related shortfalls such as limited expansion and early senescence. Human induced pluripotent stem cells (iPSCs) -derived MSCs (iMSCs) have been shown to be a useful clinically relevant source of MSCs that circumvent these ageing-associated drawbacks. The importance of this concept is manifested by the successful Phase 1 clinical trial for the treatment of GvHD by Cynata Therapeutics and the National Health Service- UK; a Phase 2 trial is planned for 2019. Note, this trial is independent of the work carried out by Spitzhorn et al.-described below.
Information Notice:
The information on this page is intended for scientific, educational, and general informational purposes. Clinical approaches, availability, and regulatory status may vary by country, institution, and medical indication. For individual medical decisions, readers should consult qualified healthcare professionals and accredited medical centers.
The information on this page is intended for scientific, educational, and general informational purposes. Clinical approaches, availability, and regulatory status may vary by country, institution, and medical indication. For individual medical decisions, readers should consult qualified healthcare professionals and accredited medical centers.
Editorial Note:
This article has been prepared by the NBScience editorial team within the scope of clinical research, biotechnology, and international medical information.
This article has been prepared by the NBScience editorial team within the scope of clinical research, biotechnology, and international medical information.
